A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation

NCT04165031 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

5

Enrollment

INDUSTRY

Sponsor class

Stopped The study was terminated due to an unexpected toxicity finding.

Conditions

Advanced Solid Tumor
Non-Small Cell Lung Cancer
Colorectal Cancer

Interventions

DRUG: LY3499446
DRUG: Abemaciclib
DRUG: Cetuximab
DRUG: Erlotinib
DRUG: Docetaxel

Sponsor

Eli Lilly and Company